"I love Innovative Medicines | Novartis"

2022-10-17 05:00:50

Skip to main contentSearchLanguage & Country Selector for DesktopGlobal |en Choose LocationInternationalAmericasAsia PacificEuropeMiddle East & AfricaGlobal | enSandoz | enNovartis Foundation | enArgentina | esBrazil | ptCanada | enCanada | frCentral America | esColombia | esMexico | esUnited States | enVenezuela | esAustralia | enBangladesh | enHong Kong S.A.R. | zhIndia | enIndonesia | enJapan | jaKorea | koMainland China | zhMalaysia | enPakistan | enPhilippines | enSingapore | enTaiwan | zhAustria | deBelgium | frBelgium | nlBulgaria | bgCzech Republic | csCzech Republic | enDenmark | daEstonia | etFinland | fiFrance | fr Germany | deGreece | elHungary | huIreland | enItaly | itLatvia | lvLithuania | ltNetherlands | nlNorway | noPoland | plPortugal | ptRomania | roRussia | ruSerbia | srSlovakia | skSpain | esSweden | svSwitzerland | deSwitzerland | frUnited Kingdom | enEgypt | enIsrael | heSouth Africa | enTurkey | trLanguage & Country Selector for MobileGlobal Choose LocationinternationalInternationalAmericasAsia PacificEuropeMiddle East & AfricaArgentina | esAustralia | enAustria | deBangladesh | enBelgium | frBelgium | nlBrazil | ptBulgaria | bgCanada | en Canada | frCentral America | esColombia | esCzech Republic | csCzech Republic | enDenmark | daEgypt | enEstonia | etFinland | fiFrance | frGermany | deGreece | elHong Kong S.A.R. | zhHungary | huIndia | enIndonesia | enIreland | enIsrael | heItaly | itJapan | jaKorea | koLatvia | lvLithuania | ltMainland China | zhMalaysia | enMexico | esNetherlands | nlNorway | noGlobal | enSandoz | enNovartis Foundation | enPakistan | enPhilippines | enPoland | plPortugal | pt Romania | roRussia | ruSerbia | srSingapore | enSlovakia | skSouth Africa | enSpain | esSweden | svSwitzerland | deSwitzerland | frTaiwan | zhTurkey | trUnited Kingdom | enUnited States | enVenezuela | esMenuAboutBoard of DirectorsJoerg ReinhardtSimon MoroneyNancy AndrewsTon BuechnerPatrice BulaElizabeth DohertyAna de Pro GonzaloBridgette HellerDaniel HochstrasserFrans van HoutenAndreas von PlantaCharles SawyersWilliam WintersCharlotte Pamer-WieserExecutive CommitteeVasant NarasimhanShreeram AradhyeJames BradnerVictor BultoAharon (Ronny) GalKaren HaleHarry KirschRob KowalskiSteffen LangKlaus MoosmayerRichard SaynorMarie-France TschudinLutz HegemannMichael WilliKees RoksStrategyPeople and CultureData and DigitalProductsInnovative MedicinesSandozDiversity & InclusionEquityDiversity & Inclusion Governance and CommunityInclusivityParental LeaveSocietyManufacturingQualityAudit programNovartis Quality Management System (QMS)Product and patient safety trainingRegulatory inspectionsProduct recallsThird-party suppliersAbout NovartisPatients and CaregiversNovartis Commitment to Patients and CaregiversDiseasesPatient Organization Funding Adverse Event ReportingCOVID-19: Patients and CaregiversStories: Patients PerspectivesPatients & CaregiversHealthcare ProfessionalsMedical Congresses and Events Abstract summaries for EULARAbstract summaries for ACRAbstract summaries for EADVProductsNovartis PipelineManaged Access ProgramsNovartis Gene Therapies Managed Access ProgramNovartis External FundingHealthcare Professional Resources by CountryInvestigator-Initiated Trials / StudiesTransparency and DisclosureNovartis Medical InformationSubmit medical enquiryHealthcare Professionals Research & DevelopmentNovartis Institutes for BioMedical ResearchCollaborationsNIBR Global Scholars ProgramTechnology PlatformsRadioligand TherapyGene TherapyCell TherapyResearch Disease AreasImmuno-oncology research at NovartisOncology research at NovartisCardiovascular and metabolic disease research at NovartisAutoimmunity, transplantation and inflammatory disease research at NovartisOphthalmology research at NovartisNeuroscience Research at NovartisMusculoskeletal Disease Research at NovartisDAx: exploratory disease research at NovartisResearch LocationsNovartis Institute for Tropical DiseasesNovartis PipelineTranslational MedicineResearch & Development ApproachResearch CollaborationsOpen Source ScienceStories from our LabsResearch & DevelopmentESGAccessCreating sustainable business modelsValue-Based PricingSub-Saharan AfricaDonationsNovartis Access PrinciplesNovartis Oncology AccessPatents and LicensingEthics, Risk and ComplianceEthical BehaviorComplianceHuman RightsLearning and EngagementRisk managementEnvironmental SustainabilityClimateWasteWaterGlobal HealthAnti-Microbial Resistance (AMR)Avoidable BlindnessChagas DiseaseLeprosyMalariaSickle Cell Disease (SCD)Novartis FoundationDiversity & InclusionReportingESG Rating PerformanceCodes, Policies and GuidelinesMateriality AssessmentTransparency and DisclosureTargetsPositionsESG IndexEnvironmental, Social and GovernanceInvestorsEvent CalendarFinancial DataNovartis Annual ResultsNovartis Quarterly ResultsNovartis SEC FilingsProduct SalesFixed-Income SecuritiesExpected Currency ImpactShare Data & AnalysisShare MonitorDividend InformationShare OwnershipShare OverviewReturn On Investment CalculatorShareholder InformationGeneral MeetingsAmerican Depository Receipts (ADR)Share Buy-BackFrequently Asked QuestionsCompany OverviewCorporate GovernanceNovartis Annual Reporting SuiteReporting ArchivePublications Order FormESGInvestorsNewsNews Archive Media Library StoriesSubscribeNewsCareersCareer SearchOur TeamsCareers in CommercialCareers in Communications and EngagementCareers in ConsultingCareers in DigitalCareers in Health, Safety & EnvironmentCareers in Information Technology (IT)Careers in Medical & DevelopmentCareers in People & OrganizationCareers in ProcurementCareers in ResearchCareers in StrategyCareers in Manufacturing and SupplyEthics, Risk & Compliance (ERC)Careers in LegalCareer ProgramsCommunity Exploration & Learning Lab (CELL)Postdoc ProgramEarly TalentUS NIBR Internship ProgramsInternational CareersPersonal GrowthWell-beingCareersCOVID-19 Information CenterCOVID-19 Novartis responseClinical TrialsClinical TrialsPartneringPartneringContactsContactsHomeHeader Innovative MedicinesPreviousNext HomeAboutInnovative MedicinesOur Innovative Medicines business is made up of two separate commercial organizations, Innovative Medicines International and Innovative Medicines US. Core therapeutic areasCardiovascularCardiovascular disease is a global health crisis. Billions of people are affected physically, emotionally and financially. Thanks to a combination of our legacy, global footprint and leading science, Novartis is uniquely positioned to help change this landscape. Our efforts include use of early interventions and development of pioneering treatments, from prevention to management, as well as the creation of innovative access models. Our goal is to reduce and ultimately stop premature death and disability from cardiovascular disease.HematologyNovartis is deeply committed to transforming the lives of people living with blood cancers and life-threatening blood disorders. Together with its research partners – Novartis led the era of targeted therapies in cancer and, in investigating how these medicines could transform patient outcomes.Solid tumorsImmunologyNovartis aims to improve outcomes and enhance the lives of those affected by painful and debilitating immunological conditions. As a result, we have already helped transform the standard of care for children and adults suffering from conditions such as psoriatic disease and axial spondyloarthritis, chronic urticaria, and a number of rare autoinflammatory diseases. We continue to focus on discovering and delivering innovative medicines for complex, less-explored immunological diseases where there is significant unmet need, such as hidradenitis suppurativa and Sjögren’s syndrome, lupus and osteoarthritis.NeuroscienceNovartis has been tackling neurological conditions for more than 80 years. Above all, partnering with patients, healthcare professionals and healthcare systems to deliver life-changing solutions and treatments is at the core of what we do. Together, we can innovate to reimagine neuroscience and improve people’s lives.OphthalmologyNovartis is reimagining the treatment and prevention of visual impairment and blindness. We aim to develop life-changing pharmaceuticals and transformative technologies for diseases and conditions from front to back of the eye.RespiratoryAt Novartis, our focus is on improving the lives of the hundreds of millions of people living with respiratory diseases, including chronic obstructive pulmonary disease (COPD) and severe allergic asthma. Novartis Global Product Portfolio and Clinical Pipeline155Countries in which products are availableSee Our Medicines30New molecular entities in our global clinical pipelineExplore Our Pipeline Understanding hidradenitis suppurativa through Jasmine’s eyesJasmine, an HS advocate, journalist and filmmaker, is one of the estimated 1 in 100 of the global population who lives with this debilitating skin disease. HS has affected every aspect of her life since she was a child.Read MoreSolving the puzzle of immunotherapyThe question of how to unlock the potential of the body’s own immune system to kill cancer cells is more than a century old. At Novartis, we are building on insight to unlock the potential of immunotherapies for more patients around the world.Read More Oncology medical meetingsExplore Our HubPreviousNextNovartis Gene TherapiesNovartis Gene Therapies is dedicated to developing and commercializing gene therapies for patients and families devastated by rare and life-threatening neurological genetic diseases.Learn More Innovative Medicines leadershipPresident, Innovative Medicines International and Chief Commercial OfficerMarie-France TschudinRead BiographyPresident, Innovative Medicines USVictor BultoRead Biography   Jobs in Innovative MedicinesMarketing InternChina, PHARMA（高级）医药代表/(资深)产品主管Sales, China, ONCOLOGYMedical Science LiaisonResearch & Development, Hong Kong Special Administrative Region, China, PHARMA（高级）医药代表 /（资深）产品主管Sales, China, ONCOLOGYAll Innovative Medicines JobsNovartisNavigate NovartisPatients and CaregiversHealthcare ProfessionalsResearchersJob SeekersJournalistsInvestorsPartnersSuppliersTopicsClinical TrialsCOVID-19 Info CenterESGExploreStoriesDiseasesLocationsProductsNovartis PipelineNovartis companiesSandozAdvanced Accelerator ApplicationsGyroscope TherapeuticsFooter Bottom © 2022 Novartis AGTerms of UsePrivacyContactsCookie SettingsSite MapWeb AccessibilityOpen SourceNovartis Site DirectoryThis site is intended for a global audience